XL184 News
Most Popular XL184 Story
XL184 - 10 promising late-stage cancer drugs
Perhaps a drug referred to as "cabo" deserves to have its day in sun. Indeed, there are plenty of folks at Exelixis ($EXEL) who are hoping that XL184 (cabozantinib) shines in clinical trials; it's Read more...
Latest Headlines
- April 12, 2011
- April 4, 2011
- February 18, 2011
- November 18, 2010
- June 21, 2010
- December 12, 2008
- October 23, 2008
- July 23, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
